Amplitude Healthcare Breaks $10.00 on First Day of Trading
by Kristi Marvin on 2019-11-20 at 11:30am

Why did Amplitude Healthcare break $10.00 on Day-One?

As previously mentioned in the SPACInsider newsletter two week ago, the fourth quarter is an especially tough time for Day-One SPAC IPO share prices, particularly in the months of November and December. In fact, as you can see below, for both 2017 and 2018, the average Day-One IPO price for the months of November and December are significantly below the monthly average for the rest of the year.  As theorized, this is due to SPAC investors protecting their end of year P&L (any sign of weakness or trouble, they’re selling) and a necessary rotation of capital to free up money for additional IPOs.  So it’s not too surprising to see Amplitude Healthcare (AMHCU) struggle on their Day-One debut, however, trading down to $9.95 IS a little surprising.  Something more like $10.00 would have been expected.

Avg. Day-1 Close Price by Month of IPO 2017-2019 YTD with data labels

 

Mostly likely in addition to the above reasons posited, there’s a real sense of deal fatigue.  We’ve had a record number of SPACs this month on top of a record year.  Plus, we have two more IPOs expected to price tonight.  Investors (and SPACInsiders) are a little weary of all the new issuance. However, there is also probably an element of BMO being a new SPAC underwriter.  SPAC investors are a unique breed and having a little SPAC pricing experience under the belt helps.

On the other hand, Software Acquisition Group Inc. (SAQNU) has traded as high as $10.08 today and if rumors are true, B. Riley cut back allocations hard.  SAQNU is B. Riley’s third left-lead deal this year, on top of three in 2018, so that additional experience certainly helps when putting together a book.

However, if the above chart is a sign of what we can expect going forward for additional Day-One prices, it’s going to be challenging.  Nonetheless, we have Cantor’s PropTech Acquisition Corp. (PTACU) pricing tonight and Cantor has been averaging a Day-One close price of $10.10 all year, so it should be interesting to see if they can maintain that average in this Q-4 IPO environment. No pressure Cantor….

Stay tuned….

 

Recent Posts
by Nicholas Alan Clayton on 2024-04-18 at 11:50am

AGBA (NASDAQ:AGBA) stock is up over +90% this morning following a +211% premarket spike on news it has signed a definitive agreement to combine with social streaming video platform Triller. AGBA, the company itself, was formed by the $555 million combination between a SPAC of the same name and TAG Companies, a financial services firm...

by Nicholas Alan Clayton on 2024-04-18 at 7:57am

At the SPAC of Dawn Since closing its combination with DHC last month, AI customer engagement firm BEN (NASDAQ:BNAI) has rolled out new partnerships with call center and healthcare clients. And, while it faces a fair bit of competition in the chatbot realm, several high-profile institutions have demonstrated that creating one that provides useful services...

by Nicholas Alan Clayton on 2024-04-17 at 3:05pm

Blue Ocean (NASDAQ:BOCN) provided significantly more texture today in the presentation for its $275 million combination with Asian digital media group TNL Mediagene, which it expects to hit profitability in the second half of the year despite a slight shakeup in financing for the transaction. The first big update in the first investor deck is...

by Nicholas Alan Clayton on 2024-04-17 at 8:13am

At the SPAC of Dawn A brand new market may have just opened up for space de-SPACs as NASA administrator Bill Nelson announced a shift in the agency’s $11 billion program for a mission to return samples from Mars. Rather than rely on the agency’s internal technologies that would be predicted to get a sample...

by Nicholas Alan Clayton on 2024-04-16 at 11:33am

Overall deal flow between SPACs and biotech firms has slowed over the last year, but some pending FDA changes could breathe new life into particular business models within the space. In particular, the FDA has asked Congress as part of its 2025 Legislative Proposals to eliminate the interchangeability designation for biosimilar medications, claiming the existing...

logo

Copyright © 2023 SPACInsider, Inc. All Rights Reserved